Search Results

You are looking at 51 - 60 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang and Zin Myint

after diagnosis adversely effects survival outcomes. Neoadjuvant chemotherapy (NAC) has become the standard of care for appropriate patients, which delays definitive surgery. Optimal timing of surgery from the time of diagnosis is uncertain when done

Full access

Jeffrey S. Montgomery, David C. Miller and Alon Z. Weizer

-based neoadjuvant chemotherapy for patients with T2–T4 localized bladder cancer followed by radical cystectomy to optimize disease outcomes. 15 Perioperative Intravesical Chemotherapy Studies dating back to the early 1990s evaluated the use of immediate

Full access

Predicted Insensitive to Standard Neoadjuvant Chemotherapy, Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC Principal Investigator: Stacy Moulder, MD Co-Investigators: Senthil Damodaran, MD; Elizabeth Mittendorf, MD, PhD

Full access

Triple-Negative Breast Cancer With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy, Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC Principal Investigator: Stacy Moulder, MD Co

Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty and Barbara A. Goff

between the diagnosis and surgery. Patients classified as receiving neoadjuvant chemotherapy consisted of those who had any claim for chemotherapy after a diagnosis of ovarian cancer and preceding claims for a surgical procedure for cancer. We also

Full access

Melinda Telli

phase II GeparSixto and CALGB 40603 trials took a different approach and set out to evaluate the role of carboplatin as an “add-on” to standard neoadjuvant chemotherapy in women with unselected triple-negative breast cancer. 1 , 2 According to the

Full access

Christopher G. Willett

%, disease-free survival was 84%, and overall survival was 91%. The authors concluded that for selected patients with clinical stage I–III rectal cancer, neoadjuvant chemotherapy and selective RT does not seem to compromise outcomes. The randomized phase

Full access

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid and Peter A. Fasching

-negative breast cancer—current status and future directions . Ann Oncol 2009 ; 20 : 1913 – 1927 . 19901010 10.1093/annonc/mdp492 4. Chaudhary LN , Wilkinson KH , Kong A . Triple-negative breast cancer: who should receive neoadjuvant chemotherapy

Full access

Junmiao Wen and Donglai Chen

into 5 subgroups: surgery alone, surgery plus adjuvant chemotherapy with or without radiotherapy, neoadjuvant chemotherapy with or without radiotherapy plus surgery and adjuvant chemotherapy with or without radiotherapy, concurrent chemoradiotherapy

Full access

Donglai Chen, Xiaofan Wang, Qifeng Ding and Yongbing Chen

neoadjuvant chemotherapy might be administered to patients with suspected stage IIIA-N2 disease? Second, given that the authors provided the number of positive lymph nodes in the tables, why was the total number of harvested nodes, which possibly affected